Skip to main content
Toggle navigation
Search
Home
Myeloma Novel Drug Targets and agents
Home
Myeloma Novel Drug Targets and agents
Myeloma Novel Drug Targets and agents
Type here to filter the list
P-259: Real-World Treatment Tendencies in Multiple Myeloma: Analysis of Drug Utilization Over Time in Brazil and Argentina
P-260: MAGNETISMM-30: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
P-261: Multiple myeloma in the era of novel agents: a single-center study
P-262: METABOLISM-ASSOCIATED GENES AS BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS FOR HYPERDIPLOID MULTIPLE MYELOMA
P-263: Disrupting the lysosome and autophagy via PIKfyve inhibition is a potential novel therapeutic approach in Multiple Myeloma
P-264: Mezigdomide (MEZI) reverses T-cell exhaustion (Tex) through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways
P-265: MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
P-266: A novel dual HDAC6 and proteasome inhibitor elicits outstanding cytotoxicity against multiple myeloma
P-267: Targeting Ubiquitin Pathway: Novel Therapeutic Approaches for Multiple Myeloma
P-268: Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses.
P-269: Pygo2 is overexpressed in myeloma cells with 1q21 amplification being involved in carfilzomib resistance
P-270: Alternative Splicing and Non-Homologous End Joining Pathways Are Vulnerabilities Associated With Loss of The Tumor Suppressor TENT5C in Myeloma
P-271: YM155 exerts anti-myeloma effects via Myc/BBC3 signaling pathway in vitro
P-272: Dual targeting of the RAS-MAPK pathway as a personized medicine approach in RASMut multiple myeloma
P-273: Inhibition of telomerase and the alternative lengthening telomere pathway induces cell death in Multiple Myeloma
P-274: Activation of the FOXO3/GSDME axis to overcome bortezomib resistance for the treatment of myeloma via pyroptosis
P-275: Targeting HVEM using a monoclonal antibody shows therapeutic promise in multiple myeloma
P-276: Vaccinating against mutated RAS in multiple myeloma: The phase I/II TG01 study
P-277:Impact of novel therapies on the overall survival of patients with multiple myeloma over the past two decades: a real-life single-center study.
P-278: Brazilian Relapsed Refractory Multiple Myeloma Patients Treated with Teclistamab Outside of Clinical Trials as an Expanded Access Program
P-279: Targeting Tryptophan Metabolism in Multiple Myeloma Offers Novel Therapeutic Approach
P-280: Elucidating the Kinase-Independent Autoregulatory Loop of PIM2 in Multiple Myeloma
P-281: Novel whole-genome DNA-damage functional screen identifies drivers of DNA damage in multiple myeloma
P-282: Evaluation of the safety and efficacy of Denosumab in patients with multiple myeloma and severe renal impairment
P-283: How to effectively administer belantamab mafodotin: Knowledge gained from the phase 1/2 BelaRd study in newly diagnosed transplant-ineligible patients with multiple myeloma
P-284: Elevated desmoglein-2 surface expression is an independent predictor of poor outcome in multiple myeloma
P-285: Identifying Anti-Viral Drugs to Sensitize and Re-Sensitize MM Cells to Chemotherapy
P-286: Indirubin-3’-monoxime Improves Immune Cell Mediated Cytotoxicity via Fatty Acid Metabolism Reprogramming in Multiple Myeloma